Zobrazeno 1 - 10
of 217
pro vyhledávání: '"J A, Neidhart"'
Publikováno v:
Music & Letters, 1959 Jan 01. 40(1), 74-75.
Externí odkaz:
https://www.jstor.org/stable/730405
Autor:
D G, Maloney, A J, Grillo-López, C A, White, D, Bodkin, R J, Schilder, J A, Neidhart, N, Janakiraman, K A, Foon, T M, Liles, B K, Dallaire, K, Wey, I, Royston, T, Davis, R, Levy
Publikováno v:
Blood. 90(6)
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates complement and antibody-dependent cell-mediated cytotoxicity and has direct antiprolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e86adb8b5cae2018840b4d97f4a29a85
https://pubmed.ncbi.nlm.nih.gov/9310469
https://pubmed.ncbi.nlm.nih.gov/9310469
Autor:
J C, Yau, J A, Neidhart, P, Triozzi, S, Verma, J, Nemunaitis, D P, Quick, D G, Mayernik, D H, Oette, F A, Haynes, J, Holcenberg
Publikováno v:
American journal of hematology. 51(4)
This is a double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating-factor (GM-CSF) after dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Fifty-six patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4679fe0ea7582eda98e8c1b63ae64660
https://pubmed.ncbi.nlm.nih.gov/8602629
https://pubmed.ncbi.nlm.nih.gov/8602629
Autor:
P J, Hollen, R J, Gralla, M G, Kris, C, Cox, C P, Belani, S M, Grunberg, J, Crawford, J A, Neidhart
Publikováno v:
Cancer. 73(8)
This study continued the development and psychometric testing of the Lung Cancer Symptom Scale (LCSS), a disease- and site-specific instrument primarily measuring the physical and functional dimensions of quality of life for individuals with lung can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8bbb3806b5c90bd4d7ebc223605a019a
https://pubmed.ncbi.nlm.nih.gov/8156514
https://pubmed.ncbi.nlm.nih.gov/8156514
Autor:
Jeffrey D. Neidhart, Edward B. Garon, Nashat Y. Gabrail, S. P. Lu, J. A. Neidhart, Moacyr Ribeiro de Oliveira, J. Balkissoon, Fairooz F. Kabbinavar
Publikováno v:
Journal of Clinical Oncology. 29:7559-7559
7559 Background: Inhibition of angiogenesis has clinical benefits in NSCLC. Depriving tumors of blood flow by adding bevacizumab (B) to other vasculature-directed agents has been hampered by toxici...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3aa1e5b2ed2c60931b0be04ab2105cb8
https://doi.org/10.1200/jco.2011.29.15_suppl.7559
https://doi.org/10.1200/jco.2011.29.15_suppl.7559
Autor:
J A, Neidhart
Publikováno v:
Cancer. 72
The introduction of hematopoietic cytokines into the clinic has been rapid with three currently approved by the Food and Drug Administration and perhaps a dozen more in clinical trials. Combinations of cytokines have been relatively unexplored in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8722b9e0315aaf66a768a60b38b4cc17
https://pubmed.ncbi.nlm.nih.gov/8242571
https://pubmed.ncbi.nlm.nih.gov/8242571
Publikováno v:
Biotechnology therapeutics. 4(3-4)
Substantial increases in dose-intensity of chemotherapy yield a severalfold increase in complete remission rates and durable responses in several types of malignant disease. Hematopoietic colony-stimulating factors decrease the duration of the result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::342b8f305c156208bd3b82303c260744
https://pubmed.ncbi.nlm.nih.gov/8292969
https://pubmed.ncbi.nlm.nih.gov/8292969
Autor:
Nashat Y. Gabrail, Jeffrey D. Neidhart, Edward B. Garon, J. Balkissoon, Fairooz F. Kabbinavar, S. P. Lu, Moacyr Ribeiro de Oliveira, J. A. Neidhart
Publikováno v:
Journal of Clinical Oncology. 28:7587-7587
7587 Background: CA4P is a small-molecule tumor vascular disrupting agent (VDA) that has shown additive effects in combination with chemotherapy and antiangiogenic therapy. This phase II study eval...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f935ecba83ea570e32ecb5e63261d8d
https://doi.org/10.1200/jco.2010.28.15_suppl.7587
https://doi.org/10.1200/jco.2010.28.15_suppl.7587
Autor:
D A, Clark, J A, Neidhart
Publikováno v:
Seminars in hematology. 29(4 Suppl 3)
GM-CSF decreases the hematopoietic toxicity of both nonablative and marrow ablative intensive chemotherapy regimens. Data are limited at this time, particularly in regard to optimal schedules and GM-CSF dosing regimens with particular chemotherapy pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bb569b4818183454b00048e2a1849a31
https://pubmed.ncbi.nlm.nih.gov/1492231
https://pubmed.ncbi.nlm.nih.gov/1492231
Autor:
J A, Neidhart
Publikováno v:
Cancer. 70
Three hematopoietic colony-stimulating factors (CSF) are currently approved for clinical use and several more are being used in clinical trials. These factors have impressive quantitative and/or functional effects on their respective target cell line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a36632ed62f6939a97055df7e776efcc
https://pubmed.ncbi.nlm.nih.gov/1379115
https://pubmed.ncbi.nlm.nih.gov/1379115